Anbio Biotechnology (NNNN)

Anbio Biotechnology Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	9.5	6.71	23.54	4.43
Revenue Growth (YoY)	8.43%	-71.49%	431.67%	-
Cost of Revenue	4.03	3.35	10.98	1.89
Gross Profit	5.47	3.36	12.56	2.54
Selling, General & Admin	1.07	1.27	2.17	0.09
Research & Development	0.26	0.13	0.2	-
Operating Expenses	1.34	1.4	2.37	0.09
Operating Income	4.14	1.96	10.2	2.46
Interest Expense	-	-	-0.01	-
Interest & Investment Income	0.29	0.17	0.04	-
Currency Exchange Gain (Loss)	-0.09	0.12	-0.26	-0
Other Non Operating Income (Expenses)	-0	0.01	0.04	0.08
Pretax Income	4.33	2.25	10.01	2.54
Net Income	4.33	2.25	10.01	2.54
Net Income to Common	4.33	2.25	10.01	2.54
Net Income Growth	184.88%	-77.49%	294.79%	-
Shares Outstanding (Basic)	42	142	-	-
Shares Outstanding (Diluted)	42	142	-	-
EPS (Basic)	0.10	0.02	-	-
EPS (Diluted)	0.10	0.02	-	-
Gross Margin	57.61%	50.07%	53.36%	57.40%
Operating Margin	43.55%	29.22%	43.30%	55.46%
Profit Margin	45.57%	33.58%	42.52%	57.26%
EBIT	4.14	1.96	10.2	2.46
EBIT Margin	43.55%	29.22%	43.30%	55.46%
Revenue as Reported	9.5	6.71	23.54	4.43

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q